Wird geladen...
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
For decades, HER2-positive breast cancer was associated with poor outcomes and higher mortality rates than other breast cancer subtypes. However, the advent of Trastuzumab (Herceptin) has significantly changed the treatment paradigm of patients afflicted with HER2-positive breast cancer. The discove...
Gespeichert in:
| Veröffentlicht in: | Cancers (Basel) |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
MDPI
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7464074/ https://ncbi.nlm.nih.gov/pubmed/32731409 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12082081 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|